Bile

Urteste has successfully developed a prototype urine-based diagnostic test for detecting brain tumours

Retrieved on: 
Martedì, Maggio 28, 2024
Lung, Bile, Prognosis, Warsaw Stock Exchange, Patent, Pancreatic cancer, Liver, Urine, FDA, Drug development, Prostate, Cancer, Ovary, Kidney, Brain, Breast, URT, Stomach, IVD, Enzyme, Medical imaging

Gdańsk, Poland – 28 MAY 2024, Urteste S.A. (Warsaw Stock Exchange: URT) biotechnology company specialising in the development of breakthrough technology to detect cancer from urine samples has developed a prototype IVD test for detecting brain tumours.

Key Points: 
  • Gdańsk, Poland – 28 MAY 2024, Urteste S.A. (Warsaw Stock Exchange: URT) biotechnology company specialising in the development of breakthrough technology to detect cancer from urine samples has developed a prototype IVD test for detecting brain tumours.
  • In the coming months, Urteste plans to start a multi- centre clinical trial in the US and Europe for its flagship project PANURI, a test for pancreatic cancer.
  • Urteste technology is non-invasive, low-cost to produce, has high sensitivity and specificity, and results are available in up to 2 hours.
  • In the coming months, Urteste plans to add the final prototypes to its pipeline and complete the prototype development phase of the tests.

Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer​

Retrieved on: 
Giovedì, Maggio 23, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Therapy, Sepsis, Patient, NAB, Retinal pigment epithelium, Bile, RAMP, Toxicity, ECOG, Febrile neutropenia, Verastem Oncology, Septic shock, BID, Clinical trial, Male, EDT, Avutometinib, Disease, Safety, Skin infection, Cancer, Pancreatic cancer, MMSc, Metastasis, ASCO, Anemia, Șaeș, Society, Eastern Cooperative Oncology Group, Mutation, Pulmonary embolism, Pneumoperitoneum, Webcast, BIW, Vomiting, DLT, Medicine, Annual general meeting, Phosphorus

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the initial interim safety and efficacy results from the ongoing RAMP 205 Phase 1/2 clinical trial evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel in the first-line in patients with metastatic pancreatic cancer.

Key Points: 
  • Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the initial interim safety and efficacy results from the ongoing RAMP 205 Phase 1/2 clinical trial evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel in the first-line in patients with metastatic pancreatic cancer.
  • We continue to progress the study evaluating other dose and schedule regimens to determine the recommended Phase 2 dose in the trial,” said John Hayslip, M.D., chief medical officer of Verastem Oncology.
  • “We look forward to Verastem presenting their initial data from the Phase 1b/2a trial of avutometinib and defactinib in combination with standard care gemcitabine and Nab-paclitaxel in previously untreated metastatic pancreatic cancer at ASCO.
  • Verastem will hold an investor conference call and webcast on Friday, May 24 at 8:00 am EDT, to discuss these data.

SwiftDuct Presents Positive Clinical Study Results of SwiftGlide For ERCP Procedures at ESGE Days 2024

Retrieved on: 
Giovedì, Maggio 2, 2024
Electrochemistry, Dielectric spectroscopy, Bar-Ilan University, Poster, Gastrointestinal Endoscopy, Trial of the century, ESGE, Fluoroscopy, Bile, Pancreatic duct, Patient, EMMS Nazareth Hospital, Pancreatitis, Galilee Medical Center, Assistant, ERCP, Clinical trial, Medical imaging

SAKHNIN, Israel, May 2, 2024 /PRNewswire/ -- In a poster presentation at the 2024 annual meeting of the European Society of Gastrointestinal Endoscopy, ESGE Days 2024, SwiftDuct announced the positive findings of the first clinical trial of SwiftGlide™, the company's electrochemical navigation system for ERCP procedures.

Key Points: 
  • SwiftDuct's first clinical study, which was conducted at Galilee Medical Center, demonstrates that the company's electrochemical navigation method has the potential to improve ERCP procedures and outcomes, marking an important milestone towards Fluoroscopy-Free ERCP cannulation.
  • ERCP is a widely used procedure to diagnose and treat issues in the bile or pancreatic ducts.
  • SAKHNIN, Israel, May 2, 2024 /PRNewswire/ -- In a poster presentation at the 2024 annual meeting of the European Society of Gastrointestinal Endoscopy, ESGE Days 2024 , SwiftDuct announced the positive findings of the first clinical trial of SwiftGlide™, the company's electrochemical navigation system for ERCP procedures.
  • The study showed that SwiftGlide™ was successful in differentiating between bile and pancreatic/mixed juices as the basis to providing selective and safe biliary cannulation during ERCP procedures.

Meta-Analysis of Data from Trials of Machine Perfusion Technologies in Liver Transplantation Demonstrates Clinical Advantages of Hypothermic Oxygenated Machine Perfusion (HOPE), according to Bridge to Life Ltd.

Retrieved on: 
Mercoledì, Maggio 1, 2024
DBD, FDA, Bile, SCS, NAS, HOPE, Systematic review, Meta-analysis, MP, Newcastle University, Transplant, Portal vein, Freeman Hospital, Research, Minuteman Library Network, Arrest, Brain death, GRADE, Liver, Patient, NMP, Health policy, Blood, Bias, Risk, Translation, Liver transplantation, DCD, Dietary supplement

CHICAGO, May 1, 2024 /PRNewswire/ -- Hypothermic oxygenated machine perfusion (HOPE) of livers awaiting transplantation provides significantly greater outcomes than normothermic machine perfusion (NMP) and ice-box static cold storage (SCS), according to a Cochrane review and meta-analysis of seven clinical trials. The analysis, Machine perfusion in liver transplantation; Cochrane review and meta-analysis, by Samuel James Tingle, MD, et al, Newcastle University, Translational and Clinical Research Institute, Newcastle, United Kingdom; Freeman Hospital, Institute of Transplantation, Newcastle, United Kingdom; Newcastle University, NIHR Blood and Transplant Research Unit, Newcastle, United Kingdom Newcastle University, Translational and Clinical Research Institute, Newcastle, United Kingdom, was shown today in a late-breaker session during The 2024 International Congress of the International Liver Transplantation Society (ILTS) in Houston, Texas.

Key Points: 
  • CHICAGO, May 1, 2024 /PRNewswire/ -- Hypothermic oxygenated machine perfusion (HOPE) of livers awaiting transplantation provides significantly greater outcomes than normothermic machine perfusion (NMP) and ice-box static cold storage (SCS), according to a Cochrane review and meta-analysis of seven clinical trials.
  • The analysis included seven randomized trials (1024 transplant recipients from 1301 randomized/included livers); four compared end-ischemic hypothermic oxygenated perfusion (HOPE) with SCS, and three compared normothermic machine perfusion (NMP) with SCS.
  • Machine perfusion (MP) is a novel method for organ graft preservation before transplantation.
  • In hypothermic oxygenated perfusion (HOPE), donor livers are perfused through the portal vein with a cold (4 °C), acellular, oxygenated fluid at low vascular pressures.

Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort

Retrieved on: 
Lunedì, Aprile 15, 2024
Cancer, Bile, FDA, Imugene, City, IMU, Immunotherapy, Recurrence, Breast, ASX, Conference, Thymic carcinoma, Disease, Patient, MAST, Lung, Pharmaceutical industry

Cholangiocarcinoma is a rare disease in which malignant cancer cells form in the bile ducts.

Key Points: 
  • Cholangiocarcinoma is a rare disease in which malignant cancer cells form in the bile ducts.
  • On Friday 12 April 2024, the Cohort Review Committee cleared the fifth cohort in the IT arm of the monotherapy dose escalation portion of the MAST trial, with no safety signals seen to date.
  • In addition to the patients dosed in the monotherapy dose escalation portion of the trial, enrolment is ongoing for the VAXINIA and pembrolizumab combination portion of the trial, with 16 patients dosed to date.
  • With no safety signals identified to date, the trial has since progressed through the monotherapy dose escalation cohorts as well as the combination study, whereby VAXINIA is administered with well-known checkpoint inhibitor pembrolizumab.

Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome

Retrieved on: 
Martedì, Aprile 2, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Itch, Medication, Alagille syndrome, Liver disease, Inflammation, Patient, Cholestasis, Bile, Cholestatic pruritus, CADTH, Liver injury, The Hospital, Liver, CDEC, Genetic disorder, PFIC, Pharmaceutical industry

“The positive reimbursement recommendation for LIVMARLI by CADTH is an important step forward for patients suffering from the debilitating effects of cholestatic pruritus related to Alagille syndrome,” said Chris Peetz, chief executive officer at Mirum.

Key Points: 
  • “The positive reimbursement recommendation for LIVMARLI by CADTH is an important step forward for patients suffering from the debilitating effects of cholestatic pruritus related to Alagille syndrome,” said Chris Peetz, chief executive officer at Mirum.
  • These patients suffer greatly from the debilitating and disruptive effects of Alagille syndrome, which often starts in early childhood.”
    “CADTH’s recommendation of reimbursement for LIVMARLI provides a meaningful advancement in the treatment of cholestatic pruritus for patients with Alagille syndrome.
  • LIVMARLI is also approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the U.S. and Europe, and for Progressive Familial Intrahepatic Cholestasis (PFIC) in the U.S. and in Europe.
  • Cholestasis in ALGS is associated with pruritus which is among the most common indications for liver transplant in ALGS.

Exposed: the dark reality of profit-driven wildlife farms

Retrieved on: 
Giovedì, Marzo 14, 2024
Elephant, Congress, Farm, Pressure, Freedom of information, Disease, Amphibian, Risk, Cannibalism, Freedom, Research, Reptile, Sale, Bird, Mammal, Mink, Zoonosis, World Animal Protection, Animal, Tourism, Breeding, Profit, Injury, Pet, Cat, Parakeet, Bile, Legislation

NEW YORK, March 14, 2024 /PRNewswire/ -- Published today, World Animal Protection's new report entitled Bred for Profit: The Truth about Global Wildlife Farming reveals for the first time the vast scale of this exploitative industry. Extensive research uncovered that billions of wild animals are bred each year and suffer on wildlife farms for uses such as "pets," entertainment, tourism, hunting, fashion, luxury goods, and traditional medicine. There is an astonishing lack of transparency and inadequate monitoring across this global multi-billion-dollar industry.

Key Points: 
  • Extensive research uncovered that billions of wild animals are bred each year and suffer on wildlife farms for uses such as "pets," entertainment, tourism, hunting, fashion, luxury goods, and traditional medicine.
  • Animals held on wildlife farms suffer from malnourishment, disease, stress-induced behaviors, injuries, infected wounds—and even cannibalism.
  • Shockingly, some captive wildlife populations are now larger than those living free.
  • World Animal Protection is urging governments worldwide to take immediate action by implementing a comprehensive and timely phase out of commercial wildlife farms and associated trade.

Herbal medicinal product: Cynarae foliumArray,Array, C: ongoing call for scientific data

Retrieved on: 
Mercoledì, Aprile 3, 2024
Asteraceae, Ethanol, Artichoke, Diarrhea, Cardoon, Spasm, Patient, Physiology, Monograph, Committee, Flatulence, Herbal medicine, Heartburn, Date, Allergy, Plant, Nausea, Sensation, Mouth, Water, Bloating, Liver, Bile, Medicine, Dietary supplement

Herbal medicinal product: Cynarae foliumArray,Array, C: ongoing call for scientific data

Key Points: 


Herbal medicinal product: Cynarae foliumArray,Array, C: ongoing call for scientific data

EQS-News: DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY

Retrieved on: 
Mercoledì, Marzo 13, 2024
Therapy, FDA, Patent, Bile, Spacecraft, Lung, GLP, Breast, Reactive oxygen species, Patient, Survival, Cell death, Melanoma, Pharmaceutical industry

DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY

Key Points: 
  • DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY
    The issuer is solely responsible for the content of this announcement.
  • DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY
    Vancouver, BC, Canada, March 4th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce the granting of US patent no.
  • 11,890,350 (‘350) by the United States Patent and Trademark Office (USPTO), broadly covering its breakthrough AccuTOX® technology.
  • This patent marks the fourth granted US patent in Defence’s ever-growing patent portfolio, which currently incudes seven published patent families.

NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Lunedì, Marzo 11, 2024
Research, GDF15, PSC, Part, Vomiting, Pregnancy, MSS, Liver, Atlas, Preterm birth, NGM, LAIR1, Nausea, Hospital, ILT3, GFRAL, Food and Drug Administration, NASH, Therapy, Woman, Toxicology, Liver disease, CRC, Cirrhosis, Biomarker, Place of birth, Colorectal cancer, Agreement, Acquisition, Plan, FGF19, AASLD, FDA, Food, Weight loss, Primary sclerosing cholangitis, Pembrolizumab, Dehydration, Bile, Hyperemesis gravidarum, HG, Patient, Pre-eclampsia, Malnutrition, Pharmaceutical industry

--On February 26, 2024, announced that it had entered into the Agreement and Plan of Merger with Atlas Neon Parent, Inc., and Atlas Neon Merger Sub, Inc.--

Key Points: 
  • The combination of NGM707 and pembrolizumab was generally well-tolerated at all four doses (200, 600, 1200, 1800 mg) of NGM707.
  • Additional details can be found in NGM Bio’s recent filings with the United States Securities and Exchange Commission (SEC).
  • NGM Bio anticipates that the Offer and the Merger contemplated under the Merger Agreement will be consummated in the second quarter of 2024.
  • If the Merger is effected, NGM Bio’s common stock will be delisted from The Nasdaq Stock Market LLC and NGM Bio will be privately held.